Drug eluting stent maker , Svelte medical, recently landed USD 16 million funding , money that company will use to commercialize its coronary stent. New Jersey based start up claims its stent to be minimal invasive in comparison to it’s counterparts and can be inserted through artery in wrist. Svelte was launched in year 2007 with a sole mission of addressing clinical issues in cardiovascular space. It has since been talked about in medical world for its low profile balloon delivered stent. Its technology to make inflammatory drug eluting stent has also be applauded by healthcare sector. Holding patent to three landmark technologies, all targeting to reduced healthcare cost and painless implantation makes company unique in comparison to its direct peers.
For more updates follow
Medical Device Trends